Validation of the Burkitt Lymphoma International Prognostic Index in patients treated with two prospective chemoimmunotherapy trials in Spain

Autor: Ribera JM, García O, Buendía-Ureña B, Terol MJ, Vicent A, Vall-Llovera F, Bergua J, García-Cadenas I, Esteve J, Ribera J, Acuña-Cruz E, Herrera P, Hernández-Rivas JM, Abrisqueta P, González-Campos J, Rodríguez C, Bastos-Oreiro M, Genescà E, Caminos N, Queipo de Llano MP, Cladera A, Sancho JM, Members of PETHEMA: Josep-Maria Riberaa, Olga Garcíaa, Ferran Vall-Lloverae, Jua

Publikováno v: Leukemia & lymphoma
r-IIS La Fe. Repositorio Institucional de Producción Científica del Instituto de Investigación Sanitaria La Fe
instname

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=RECOLECTA___::b9a1fdc3971f354a7ba22d7e64d8f523
https://fundanet.iislafe.san.gva.es/publicaciones/ProdCientif/PublicacionFrw.aspx?id=15649

Favorable outcome of patients with acute myeloid leukemia harboring a low-allelic burden FLT3-ITD mutation and concomitant NPM1 mutation: relevance to post-remission therapy

Autor: Pratcorona M, Brunet S, Nomdedeu J, Maria Ribera J, Tormo M, Duarte R, Escoda L, Guardia R, Queipo de Llano MP, Salamero O, Bargay J, Pedro C, Maria Marti J, Torrebadell-Burriel M, Diaz-Beya M, Camós-Guijosa M, Colomer D, Hoyos M, Sierra J, Esteve J, Grp Cooperativo Estudio

Publikováno v: Blood
r-FSJD: Repositorio Institucional de Producción Científica de la Fundació Sant Joan de Déu
Fundació Sant Joan de Déu
r-FSJD. Repositorio Institucional de Producción Científica de la Fundació Sant Joan de Déu
instname

Risk associated to FLT3 internal tandem duplication (FLT3-ITD) in patients with acute myeloid leukemia (AML) may depend on mutational burden and its interaction with other mutations. We analyzed the effect of FLT3-ITD/FLT3 wild-type (FLT3wt) ratio de

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=dedup_wf_001::47bec6d37c293bd69fe4044c670c5889
http://fundanet.fsjd.org/Publicaciones/ProdCientif/PublicacionFrw.aspx?id=8634

The lincRNA HOTAIRM1, located in the HOXA genomic region, is expressed in acute myeloid leukemia, impacts prognosis in patients in the intermediate-risk cytogenetic category, and is associated with a distinctive microRNA signature

Autor: Díaz-Beyá, Marina, Brunet Mauri, Maria Salut, Nomdedeu, Josep, Pratcorona, Marta, Cordeiro, Anna, Gallardo, David, Escoda, Lourdes, Tormo, Mar, Heras, Inmaculada, Ribera, Jose-Maria, Duarte, Rafael, Llano Queipo, María Paz de, Bargay, Joan, Sampol, Antonia, Nomdedeu, Meritxell, Risueño, Ruth M., Hoyos Colell, Montserrat, Sierra Gil, Jorge, Monzo, Mariano, Navarro, Alfons, Esteve Reyner, Jordi, Cooperative AML group CETLAM, Universitat Autònoma de Barcelona

Publikováno v: Oncotarget
r-IIB SANT PAU. Repositorio Institucional de Producción Científica del Instituto de Investigación Biomédica Sant Pau
instname
Europe PubMed Central
Dipòsit Digital de la UB
Universidad de Barcelona
Recercat. Dipósit de la Recerca de Catalunya
Dipòsit Digital de Documents de la UAB
Universitat Autònoma de Barcelona

Long non-coding RNAs (lncRNAs) are deregulated in several tumors, although their role in acute myeloid leukemia (AML) is mostly unknown. We have examined the expression of the lncRNA HOX antisense intergenic RNA myeloid 1 (HOTAIRM1) in 241 AML patien

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::363669f60cd22dc578629ec6036d0e3e
https://www.scopus.com/inward/record.uri?eid=2-s2.0-84945568293&doi=10.18632/oncotarget.5148&partnerID=40&md5=52230923b31c155eb0df41820cea86be

Outcomes and prognostic factors of adults with refractory or relapsed T-cell acute lymphoblastic leukemia included in measurable residual disease-oriented trials.

Autor: Ribera JM; Hematology Department, Institut Català d'Oncologia, Hospital Germans Trias i Pujol, Josep Carreras Research Institute, Universitat Autònoma de Barcelona, Barcelona, Spain., Morgades M; Hematology Department, Institut Català d'Oncologia, Hospital Germans Trias i Pujol, Josep Carreras Research Institute, Universitat Autònoma de Barcelona, Barcelona, Spain., Genescà E; Hematology Department, Institut Català d'Oncologia, Hospital Germans Trias i Pujol, Josep Carreras Research Institute, Universitat Autònoma de Barcelona, Barcelona, Spain., Chapchap EC; Hematology Department, Hospital Israelita Albert Einstein, Sao Paulo, Brazil., Montesinos P; Hematology Department, Hospital Universitari i Politènic La Fe, Valencia, Spain., Acuña-Cruz E; Hematology Department, Hospital Universitari i Politènic La Fe, Valencia, Spain., Gil C; Hematology Department, Hospital General de Alicante, Alicante, Spain., García-Cadenas I; Hematology Department, Hospital de Sant Pau, Barcelona, Spain., Barba P; Hematology Department, Hospital Universitari Vall d'Hebron, Barcelona, Spain., González-Campos J; Hematology Department, Hospital Universitario Virgen del Rocío, Sevilla, Spain., Queipo de Llano MP; Hematology Department, Hospital Universitario Virgen de la Victoria, Málaga, Spain., Torrent A; Hematology Department, Institut Català d'Oncologia, Hospital Germans Trias i Pujol, Josep Carreras Research Institute, Universitat Autònoma de Barcelona, Barcelona, Spain., Ribera J; Hematology Department, Institut Català d'Oncologia, Hospital Germans Trias i Pujol, Josep Carreras Research Institute, Universitat Autònoma de Barcelona, Barcelona, Spain., Granada I; Hematology Department, Institut Català d'Oncologia, Hospital Germans Trias i Pujol, Josep Carreras Research Institute, Universitat Autònoma de Barcelona, Barcelona, Spain., Bernal T; Hematology Department, Hospital Central de Asturias, ISPA, IUOPA, Oviedo, Spain., Díaz-Beyá M; Hematology Department, Hospital Clínic, Barcelona, Spain., Amigo ML; Hematology Department, Hospital Morales Meseguer, Murcia, Spain., Coll R; Hematology Department, Institut Català d'Oncologia, Hospital Josep Trueta, Girona, Spain., Tormo M; Hematology and Oncology Department, Instituto de investigación INCLIVA, Hospital Clínico Universitario, Valencia, Spain., Vall-Llovera F; Hematology Department, Hospital Universitari Mútua de Terrasa, Terrassa, Spain., Gómez-Centurión I; Hematology Department, Hospital General Universitario Gregorio Marañón, Madrid, Spain., Sánchez-Sánchez MJ; Hematology Department, Hospital Universitario Lucus Augusti, Lugo, Spain., Soria B; Hematology Department, Hospital Universitario de Canarias, Santa Cruz de Tenerife, Spain., Cladera A; Hematology Department, Hospital Son Llàtzer, Palma de Mallorca, Spain., Artola MT; Hematology Department, Hospital Universitario de Donostia, Donostia, Spain., Garcia-Guiñon A; Hematology Department, Hospital Arnau de Vilanova, Lleida, Spain., Giménez-Conca A; Hematology Department, Hospital Italiano de Buenos Aires, Buenos Aires, Argentina., Amador ML; Hematology Department, Complejo Hospitalario de Pontevedra, Spain., Martínez-Sánchez P; Hematology Department, Hospital 12 de Octubre, Madrid, Spain., Algarra JL; Hematology Department, Hospital General Universitario Albacete, Albacete, Spain., Vidal MJ; Hematology Department, Hospital Universitario de León, León, Spain., Alonso N; Hematology Department, Hospital Universitario Santiago de Compostela, Santiago, Spain., Maluquer C; Hematology Department, Institut Catala d'Oncologia-Hospital Duran y Reynals, L'Hospitalet de Llobregat, Barcelona, Spain., Llorente L; Hematology Department, Hospital HM Sanchinarro, Madrid, Spain., García-Boyero R; Hematology Department, Hospital General Universitario de Castellón, Castellón, Spain., Ciudad J; Hematology Department, Centro de Investigación del Cáncer, IBSAL, IBMCC, CIBERONC, Hospital Universitario, Universidad de Salamanca-CSIC, Salamanca, Spain., Feliu E; Hematology Department, Institut Català d'Oncologia, Hospital Germans Trias i Pujol, Josep Carreras Research Institute, Universitat Autònoma de Barcelona, Barcelona, Spain., Orfao A; Hematology Department, Centro de Investigación del Cáncer, IBSAL, IBMCC, CIBERONC, Hospital Universitario, Universidad de Salamanca-CSIC, Salamanca, Spain.

Publikováno v: Hematological oncology [Hematol Oncol] 2021 Oct; Vol. 39 (4), pp. 529-538. Date of Electronic Publication: 2021 Aug 18.

Bone marrow VEGFC expression is associated with multilineage dysplasia and several prognostic markers in adult acute myeloid leukemia, but not with survival.

Autor: Guillem V; a Department of Hematology and Medical Oncology , Hospital Clínico Universitario INCLIVA Biomedical Research Institute , Valencia , Spain., Calabuig M; a Department of Hematology and Medical Oncology , Hospital Clínico Universitario INCLIVA Biomedical Research Institute , Valencia , Spain., Brunet S; b Department of Hematology , Hospital de Sant Pau, IIB Sant Pau and Jose Carreras Leukemia Research Institutes, Universidad Autónoma de Barcelona , Spain., Esteve J; c Department of Hematology , Hospital Clínic, IDIBAPS , Barcelona , Spain., Escoda L; d Department of Hematology , Hospital Universitari Joan XIII , Tarragona , Spain., Gallardo D; e Department of Hematology , ICO Girona, Hospital Josep Trueta, IDIBGI Foundation , Girona , Spain., Ribera JM; f Department of Hematology , ICO Badalona - Hospital Germans Trias i Pujol, Josep Carreras Leukemia Research Institute, Universitat Autonoma de Barcelona , Badalona , Spain., Queipo de Llano MP; g Department of Hematology , Hospital Virgen de la Victoria , Málaga , Spain., Arnan M; h Department of Hematology , ICO - Hospital Duran i Reynals , Barcelona , Spain., Pedro C; i Department of Hematology , Hospital del Mar, Parc de Salut Mar , Barcelona , Spain., Amigo ML; j Department of Hematology , Hospital Morales Meseguer , Murcia , Spain., Martí-Tutusaus JM; k Hospital Universitari Mútua Terrassa , Terrasa , Spain., García-Guiñón A; l Department of Hematology , Hospital Universitari Arnau de Villanova , Lleida , Spain., Bargay J; m Department of Hematology , Hospital Son Llatzer , Mallorca , Spain., Sampol A; n Department of Hematology , University Hospital Son Espases, Instituto IDISPA , Palma de Mallorca , Spain., Salamero O; o Department of Hematology , Hospital Vall d'Hebron , Barcelona , Spain., Font L; p Department of Hematology , Hospital Verge de la Cinta , Tortosa , Spain., Talarn C; c Department of Hematology , Hospital Clínic, IDIBAPS , Barcelona , Spain., Hoyos M; b Department of Hematology , Hospital de Sant Pau, IIB Sant Pau and Jose Carreras Leukemia Research Institutes, Universidad Autónoma de Barcelona , Spain., Díaz-Beyá M; c Department of Hematology , Hospital Clínic, IDIBAPS , Barcelona , Spain., Garrido A; b Department of Hematology , Hospital de Sant Pau, IIB Sant Pau and Jose Carreras Leukemia Research Institutes, Universidad Autónoma de Barcelona , Spain., Navarro B; a Department of Hematology and Medical Oncology , Hospital Clínico Universitario INCLIVA Biomedical Research Institute , Valencia , Spain., Nomdédeu J; b Department of Hematology , Hospital de Sant Pau, IIB Sant Pau and Jose Carreras Leukemia Research Institutes, Universidad Autónoma de Barcelona , Spain., Sierra J; b Department of Hematology , Hospital de Sant Pau, IIB Sant Pau and Jose Carreras Leukemia Research Institutes, Universidad Autónoma de Barcelona , Spain., Tormo M; a Department of Hematology and Medical Oncology , Hospital Clínico Universitario INCLIVA Biomedical Research Institute , Valencia , Spain.

Publikováno v: Leukemia & lymphoma [Leuk Lymphoma] 2018 Oct; Vol. 59 (10), pp. 2383-2393. Date of Electronic Publication: 2018 Jan 18.